Group Resources

Annual Report

COSA Annual Report 2023

Endorsed Resources

CNSA Vascular Access Devices: Evidence-Based Clinical Practice Guidelines

The CNSA Vascular Access Devices: Evidence-Based Clinical Practice Guidelines, 2024 provide recommendations for clinical practice based on current evidence. This knowledge base, alongside your clinical expertise, individual patient preferences, products and their appropriate application, and finally within your local workplace or environment can be integrated together into comprehensive approach to vascular access management for the individual cancer patient.

Annual Report

COSA Annual Report 2022

Submissions

Submission to the draft Australian Cancer Plan

Endorsed Resources

Urgent action needed to stop young people using e-cigarettes

More and more young Australians are using e-cigarettes. These are harmful to health and can cause nicotine
addiction, poisoning, seizures, burns and lung injury. The long-term harms are not yet known. Non-smokers who use e-cigarettes are much more likely to go on to smoke tobacco.

This is a rapidly accelerating public health crisis. Cancer Council and other public health groups call on governments to take immediate action—before it is too late.

Endorsed Resources

E-cigarette use in young people - urgent action needed to avert a public health crisis

The only way to halt the epidemic of e-cigarette use among young people is to significantly strengthen enforcement of existing laws and enact additional legislative controls. Read the recommendations from Cancer Council, COSA and other leading public health organisations.

Position Statement

Tumour screening for mismatch repair deficiency (Lynch syndrome)

This position statement recommends the development of a national strategy of universal dMMR tumour screening in all newly diagnosed colorectal and endometrial cancers. This will allow the identification of families with Lynch Syndrome, as well as inform the clinical care of cancer patients. We recognise the need for education of clinicians and the public about Lynch Syndrome, and the provision of adequate laboratory and clinical genetics resources to enable full ascertainment of Australian Lynch Syndrome families and realise the individual and population-level health benefits of their ascertainment.

Group Chair

Group Chair Image
Group Chair

Nik Zeps

Cancer Biology Group Chair